Skip to content

Use of Baclofen (drug) in alcohol intake patients.

Efficacy of Baclofen Vs Naltrexon in Achieving & Maintaining Abstinence in Alcohol Dependence. - NIL

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/01/061476
Enrollment
110
Registered
2024-01-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K703- Alcoholic cirrhosis of liver

Interventions

Intervention1: Naltrexone: Naltrexone 50mg orally once daily will give for 12 weeks Control Intervention1: Baclofen: Baclofen 10mg orally thrice daily will give for 12 weeks

Sponsors

Institute of Liver and Biliary Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All consecutive alcohol related compensated cirrhotic patients with continued alcohol consumption despite counselling in last 4 weeks aged between 18 - 65yrs 2. Fulfilling DSM – 5 criteria for alcohol use disorder (Association, 2013) 3. History of recent recidivism / relapse

Exclusion criteria

Exclusion criteria: 1. Current HE 2. Total Bilirubin > 5 mg/dl 3. Recent bleed 4. Treatment with corticosteroids within the past 60 days 5. Unwilling to participate 6. Dependence on any other substance (except Nicotine) 7. Psychotic disorder requiring treatment

Design outcomes

Primary

MeasureTime frame
The comparison in the proportion of patients achieving and maintaining alcohol abstinence between Naltrexone and Baclofen in alcohol associated liver cirrhosis patients with continued alcohol intake at 12 weeksTimepoint: 12 weeks

Secondary

MeasureTime frame
To evaluate difference in alcohol free days between groups at 4, 8,12 and 24 weeksTimepoint: 4, 8,12 and 24 weeks;To evaluate difference in craving measures between groups at 4, 8,12 and 24 weeksTimepoint: 4, 8,12 and 24 weeks;To evaluate drinking pattern before and after 4 week on Naltrexone without liver related adverse effects compared to baclofenTimepoint: 4 weeks;To evaluate proportion of patients developing lapse and relapse in both the group at 4,8,12 and 24 weeksTimepoint: 4,8,12 and 24 weeks;To evaluate proportion of patients maintaining abstinence from alcohol in both the group at 24 weeksTimepoint: 24 weeks;To evaluate the progression of liver disease in both groupTimepoint: 24 weeks

Countries

India

Contacts

Public ContactDr Shasthry S M

Institute of Liver and Biliary Sciences

shasthry@gmail.com01146300000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026